chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Post 2nd Hep B vax, child had rash within 24 hrs.
I contracted COVID on or around 9/10. 9/13 I had symptoms like a cold/flu but temperature was not high. 9/17 I lost my sense of taste and then had a COVID Test at Urgent Care where I tested positive. I then quarantined for 10 days. My taste came back after 10 days.
29Sept95 pt recv 1 dose vax. 18Feb98 pt exp chickenpox consisting of approx 20 lesions.
No adverse event; Patient received vaccine pass 3 days of expiry; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received vaccine pass 3 days of expiry) and NO ADVERSE EVENT (No adverse event) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 051B22A and 018F21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Tdap vaccine in 2021. Past adverse reactions to the above products included No adverse event with Tdap vaccine. Concurrent medical conditions included Asthma, Hypertension and Prediabetes. Concomitant products included GABAPENTIN, LOSARTAN, OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]), MONTELUKAST SODIUM (SINGULAIR), COLECALCIFEROL (VITAMIN D3) and PNEUMOCOCCAL VACCINE for an unknown indication.   On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 14-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 18-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .25 milliliter. On 30-Aug-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .25 milliliter. On 30-Aug-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received vaccine pass 3 days of expiry). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received vaccine pass 3 days of expiry) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Patient received vaccine pass 3 days of expiry).    Number of doses/vials were dose 1 and vial 1 vial did not undergo any temperature excursions. patient not had COVID positive test or diagnosis. Treatment medications were not reported.   Most recent FOLLOW-UP information incorporated above includes: On 31-Aug-2022: Follow-up information received contains Contact Information updated.
fluttering in chest; headache; fatigue; diarrhea; swollen lymph nodes; This is a spontaneous report from a non-contactable consumer or other non hcp. A 58-years-old female patient received bnt162b2 (BNT162B2) solution for injection dose 1 (Lot Number: FA7485 expiry date was unknown) via an unspecified route of administration at arm left on 10Aug2021 15:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 from an unknown date and unknown if ongoing if covid_prior_vaccination: Yes. Concomitant medication(s) included alprazolam (XANAX), vitamin d (vitamin d nos), multivitamins and HRT. No pregnancy at time of Vaccination. The patient had received any other vaccines within 4 weeks prior to the COVID vaccine. List of any other medications the patient received within 2 weeks of vaccination: Xanax, multivitamins, vitamin D, HRT. Prior to vaccination the patient had diagnosed with COVID-19. Since the vaccination the patient has been tested for COVID-19. Patient had no known allergies. On 11Aug2021 07:00 the patient experienced fluttering in chest, headache, fatigue, diarrhoea and swollen lymph nodes. The patient underwent lab tests and procedures which included sars-cov-1 test: positive on an unspecified date patient had covid_prior_vaccination. No treatment was given. Outcome of the events was recovering.   No follow-up attempts are possible. No further information is expected.
Patient experienced itching on chest, chin, lips, and arms. Suggestion was made to patient to seek advice of physician for follow up. At this point not sure if needed to follow up with physician.
Started as a red circle around the injection site.  On 1/24/2011, redness is raised, itchy, a little warm, and 3-4" X 1" in size. Patient reports no fever.
no other AE occurred; dose of ROT ATEQ that was administered after the expiration date.; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. No information regarding the patient's concurrent conditions, medical history, drug reactions or allergies and concomitant medications was provided.  On 12-JUL-2021, the patient was vaccinated with expired dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # 1691140, expiration date: 10-JUL-2021, dose reported as 1 dose, orally (dose number and exact dose were not reported) for prophylaxis. No adverse event occurred.
diarrhea for 10 days, now with visible blood and hemoccult positive; supportive outpatient care only, DO NOT SUSPECT INTUSSCEPTION
large bruise at the injection site of the left deltoid; tenderness of the site the same day of the injection; Initial information received on 08-Oct-2020 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 78 year old female patient who experienced tenderness of the site the same day of the injection (Vaccination site pain) and large bruise at the injection site of the left deltoid (Vaccination site bruising), while she received INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  Medical history, medical treatments, vaccinations, concomitant medications and family history were not provided.   On 25-Sep-2020, the patient received a 1 dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot number UJ516AA expiration date: 30-Jun-2021) via unknown route in the left deltoid for immunisation.  On 25-Sep-2020, the patient developed a non-serious tenderness of the site the same day of the injection (vaccination site pain) same day following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  On an unknown date, the patient developed a non-serious large bruise at the injection site of the left deltoid (vaccination site bruising) 72 hours after following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE. Bruising was the size of a softball and located more toward the lateral side or back of the arm. Patient reported that the bruise was located more toward the area of the skin was bunched up to give the injection and that the bruise was healing but was still taking up a large area.  Final diagnosis was tenderness of the site the same day of the injection and large bruise at the injection site of the left deltoid.  No relevant laboratory tests were reported.   It was not reported if the patient received a corrective treatment.  Event outcome was reported as not resolved for both the events
pt recv vax; devel swelling & induration 3-4 days later; myositis; area inc swelling & devel erythema adm to hosp had I&D & IV ATBs;B-hemolytic strep;
patient reports fasting high blood sugar >200 12+ hours after vaccination - she is diabetic on oral metformin and has never had elevated blood sugar >140 with fasting; controlled HgA1C at 6.1%; felt dizzy, nauseated, HA and sweaty as if she may pass out - never passed out
This is my first Flu vaccine which was administered at 10:15am on Monday, Nov 5th.  Within an hour I started experiencing a moderately severe headache and spent two days in bed with fever and chills.  Note:  I am extremely sensitive to medication.
Vaccine breakthrough. Patient fully vaccinated and was hospitalized on 7/25/21. Transferred to SNF on 8/3/21.
Pain and swelling, acute inflammation at injection site within 24 hours of Td vaccine injection.
burning rash on bilateral thighs  - treated with Triamcinolone 0.1% cream
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 59-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 24Sep2022 at 12:00 as dose 5 (booster), single (Lot number: G75342) at the age of 59 years, in right arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 04Feb2021 as dose 1, single (Lot number: EM9810), in left arm, on 10Mar2021 as dose 2, single (Lot number: EN6198), in left arm, on 31Dec2021 as dose 3 (booster), single (Lot number: FF2593), in left arm and on 19Apr2022 as dose 4 (booster), single (Lot number: FK9895), in left arm for covid-19 immunisation. The patient had no relevant medical history. Patient has no known allergies. Concomitant medication(s) included: LOVASTATIN, start date: Jan2017. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "not recovered" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19. Patient took Paxlovid on 25Oct2022 to 30Oct2022 for treatment of COVID-19.
Child was given DtaP/IPV at 9 yrs of age.  Vaccine is not licensed for use at this age.  Per conversation with mother no adverse effects noted.
08/11/21 3:20-3:47 p.m. Pain at left arm injection site; pain radiating into chest; tightness in chest; tightness in jaw; tightness in throat; dry mouth; numbness in upper left arm radiating into lower arm up to wrist area. 3:47 p.m - Lightheaded; dizzy, naseaus; tightness in jaw. 3:55 p.m. heavy legs, naseaus. 8/12/21 Naseau and vomitting, more pain at injection site from 7:40 a.m. to 10:00 a.m 10:20 a.m. Pains in lower abdomen; gas.  11:30 am - Disoriented. 11:55 am, Diarrhea. 1:00 p.m. Fatigue, metallic tast in mouth, sleepy. 2:05 pm Migraine Headache. 2:30 p.m. (and into the evening night's sleep) Feber of 100. Slept for 2 hours. 8:00 p.m. naseau, headache, pain in teeth and jaw, still fever. 8:30 p.m Low back
Information has been received from a certified medical assistant concerning a female who on 20-DEC-2007 was vaccinated with the first dose of GARDASIL (lot# 659441/1446U) IM. On 17-JUL-2008 the patient was vaccinated with the second dose of GARDASIL (lot# 659964/1978U) IM. Concomitant therapy included WELLBUTRIN and oral birth control. On 17-JUL-2008 the patient experienced pain at injection site after the vaccination. The patient sought medical attention in office. Additional information has been requested. This is in follow-up to report(s) previously submitted on 08/14/2008 Information has been received from a certified medical assistant concerning a female patient who on 20-DEC-2007 was vaccinated with the first dose of GARDASIL (lot # 659441/1446U) IM. On 17-JUL-2008  the patient was vaccinated with the second dose of GARDASIL (lot#659964/1978U) IM. Concomitant therapy included WELLBUTRIN and oral birth control. On 17-JUL-2008 yje patient experienced pain at injection site after the vaccination. The patient sought medical attention in office. Additional information has been requested.
COVID 19 Moderna EUA., first shot.  Exactly one week after vaccine, I began experiencing itching.  The following day the injection site was still itching, but was now red, and  bumpy.  It is also slightly swollen.  I am experiencing no other symptoms.    I spoke to a physician on telemedicine.  He agreed that it was an allergic reaction to the Moderns vaccine.  He recommended no further action, as I have no fever or pain.
Upper arm at injection site become swollen and red: center of medial deltoid was inflamed and elevated approximately 3cm in height x4cm w and 3cm long, elevated area was the center of a 6x7cm red- dark red circular area with undefined edges, distal to injection sight appeared. This area progressed from red to almost Burgundy before fading by day 5. Area was hot and extremely painful. Left axilla was hot, painful on gentle palpation, lymph nodes were swollen and pain was diffuse into left pectoral area. She had general malaise, mild flu like symptoms and discomfort for 5 days. Area returned to normal around June 2. Treated discomfort with 7.5ml ibuprofen Q 4 hours and topical cortisone cream.
Dizziness HA since Vacc #1 Migraine after Vacc #2 Now arms are tingling/numbness occasionally left arm numb.
Rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced RASH (Rash). At the time of the report, RASH (Rash) outcome was unknown.            No concomitant medications were reported.  Treatment details included that the patient had not taken any medications and did not visited his HCP. Action taken for Moderna COVID-19 vaccine was not applicable. Patient developed rash on his ankle on 17 March 2021 which is still same.
Headache, fatigue, fever, swelling and soreness at shot site  Took Aleve for fever 10 days after shot, shot site became feverish and ached.  Red place around  shot site 2.5 inch round, some bruising coloration
March 3rd I had chills for about 4-6 hours.  My arm was sore for 3 days.  March 4th, I had a headache & felt like I had a head cold with sneezing and stuffy nose.  My right ear was itching.  I had bouts of chills that lasted 4-6 hours that day as well.  March 5th  I had another bout of chills that lasted about 4-6 hours.  On March 6th, I had intense fatigue and slept the entire day and night.  Then on March 15th, I broke out in a big rash on my left arm where the 1st vaccine was given and around my stomach.  My arm was very sore, was hot to the touch and very hard. On March 16th, it was still very red, super itchy and hot to the touch.  My doctor told me to take antihistamines and Advil.  She never actually saw me nor looked at my arm.  She stated it was "normal" and I should have the 2nd vaccine.  However, today my arm is the same or slightly worse.  There is less itching, likely from the antihistamines and cortisone cream.  My friend told me I should report this and should reconsider getting the second dose, given my history of severe reactions.
Scattered maculopapular rash on chest.  Afebrile. No adenopathy noted.
Case number PHEH2013US007828 is an initial spontaneous report from the nurse received on 04 Apr 2013. This report refers to a patient of an unknown age and gender. On an unknown date, the patient was accidentally vaccinated with only the MenCYW-135 liquid component of MENVEO (batch number: not reported) intramuscularly and did not receive Men A lyophilized conjugate. The nurse again gave a correctly reconstituted dose of MENVEO to the patient. It was reported that the patient did not experience any adverse event after these mal-administrations. No other information was available.
This case was reported by a other health professional and described the occurrence of expired vaccine used in a 37-year-old female patient who received ENGERIX B adult (batch number AHBVC095CA, expiry date 17th May 2014). On 13th November 2014, the patient received the 1st dose of ENGERIX B adult (unknown). On an unknown date, an unknown time after receiving ENGERIX B adult, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown. Additional information received on 14 November 2014: The expired dose was inadvertently administered. No adverse event was reported.
Second vaccine on FRIDAY and left arm was sore later that evening.   SATURDAY I slept a lot.  I couldn't drink water as it made me nauseated.  I developed a headache in the early afternoon followed by nausea.  Movement nauseated me.  I managed three spoonfuls of soup and one piece of buttered bread. SUNDAY I felt better and was able to finish my soup and two slices of buttered bread.  Still very sore. MONDAY I noticed a slight rash on the left side of my neck that had crawled up to my jaw and ear. It didn't itch so much as it felt like the sensation of novocaine wearing off.  Also noticed what appeared to be a rash on the back side of my armpit and a hard lump.  I seemed to have some lack of balance - maybe from the rash that had gone into my ear. TUESDAY I noticed the rash had also claimed the right side of my neck and jaw though not as pronounced. FYI: I chose the Moderna because my 95 year old mother was given that vaccine and had only a sore arm - both times.  I figured if I choose the Pfizer and had an adverse reaction she would tell me "You should have chosen the Moderna!"  Well, I chose the Moderna and look what happened!! :-D
PATIENT WAS ADMINISTERED EXPIRED PREVNAR-13 VACCINE. EXPIRATION DATE 6/30/2023. PATIENT WAS MONITORED FOR 30 MINUTES BY MD AND RN. NO ADVERSE REACTIONS NOTED. MANUFACTURE OF THE VACCINE CONTACTED FOR POSSIBLE RECOMMENDATIONS AND FOLLOW UP.
This is a prospective pregnancy case. This female subject was enrolled in an open label study. The subject received BOOSTRIX .5 ml on 22nd January 2015. On an unknown date, an unknown time after receiving BOOSTRIX the subject developed drug exposure during pregnancy (Non-serious). The outcome of drug exposure during pregnancy was unknown. The pregnancy was ongoing. Additional details provided: Due date and gestational age were unknown.
Patients received some Moderna COVID19 doses that were expired; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patients received some Moderna COVID19 doses that were expired) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Sep-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Sep-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patients received some Moderna COVID19 doses that were expired). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patients received some Moderna COVID19 doses that were expired) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Patient received booster dose.  No treatment medications were reported.
This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and gender. No information on the patient's concomitant medications, pertinent medical history, drug reactions or allergies was reported. On 07-JUN-2017, the patient was inadvertently vaccinated with an expired dose of M-M-R II (lot # L019989 with expiry date on 01-JUN-2017; dose and route of administration were not reported) for prophylaxis. This was supported as per stability memo. No adverse effects were reported. Additional information has been requested.
Patient was in his usual state of health, working fulltime as a mechanic (history of overweight, gastroescophageal reflux, alcohol abuse, hyperlipidemia). Received Moderna Covid 19 vaccines on 9/11/21 and 10/16/21.  November 2021 he had sudden onset of back pain, noted to have compression fracture 11/29/21, By 10/12/22 all thoracic and lumbar vertebrae with compression fractures, spontaneous rib fractures.   2/2022:  diagnosed with iron deficiency anemia Appears to have developed extensive kidney cysts  between  scan 11/29/21 and 10/12/22 based on changes note in imaging.  6/2022 diagnosed with severe osteopenia Developed Adrenal Insufficiency, dx with a pituitary microadenoma
Hives all over the body; Initial information was received on 26-Aug-2020 regarding an unsolicited valid non-serious case received from a nurse.  This case is linked to case 2020SA232560, 2020SA230493 and 2020SA231710 (same reporter).  This case involves a male patient(age between 20-30 years) who experienced hives all over the body (urticaria), while he received vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  No concomitant medication was given.   On an unknown date, the patient received 0.5 mL (once) dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (Pre-filled syringe) (lot UJ432AB and expiry date 30-Jun-2021) via unknown route in the deltoid(not otherwise specified) for prophylactic vaccination.  On an unknown date, the patient developed non-serious hives all over the body (urticaria) (Unknown latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  Details of laboratory data were not reported.   It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event was reported as unknown.
Resident delivered and started coughing a few days prior to delivery. Symptoms progressed to post-tussive vomiting and paroxysmal coughing during duration of illness. Child had symptoms of Pertussis on 10/14/17 and tested PCR positive. The symptom start date for the mother in comparison to vaccine date indicates evidence of vaccine failure.
Information has been received from a nurse referring to an unknown number of patients of unknown age and gender. In 2015 these patients were vaccinated with doses of GARDASIL (lot# K023432 with expiration 18-JUN-2016; lot# was reported as K028247 with expiration 29-JAN-2017; lot # L010696 with expiration 06-APR-2017; dose, frequency and route were not reported), which had been improperly stored since January 2015. No adverse effects were reported. This is one of several cases received from the same source. Additional information has been requested.
Information has been received from a registered nurse concerning a 22 year old female who on 22-JAN-2007 was vaccinated with 0.5mL IM, first dose, Gardasil (lot# 655165/1425F). Concomitant therapy included Seasonale. On 23-JAN-2007 the patient experienced fever of 103F and nausea. The patient sought unspecified medical attention and did not require lab diagnostic studies to be performed. Subsequently, the patient recovered from fever of 103F and nausea after the injection x 2 days. The patient also experienced nausea (was nauseated). The patient sought unspecified medical attention and did not require lab diagnositc studies to be performed. Subsquently, the patient recovered completely. Additional information has been requested. This is in follow-up to report (s) previously submitted on 4/13/2007. Additional attempts to contact the patient had been unsuccessful sin 27-Mar-2007 when she reported the reaction. At the time of this report, the patient had not returned for ther second GARDASIL. No product quality comlaint was involved. No further information is available.
Diarrhea  at 5:40am on 1/6/21  ,  39 hours after getting the moderna Covid 19 Vaccine. No warning just watery  and uncontrollable for a couple of hours . It was like I had taken colonoscopy prep. I ate dinner at 6 pm 1/5/21 and only had water to drink over night  and in am before it started. It  No stomach cramping noted. I do not know of anyone that I have had contact with who has had diarrhea in the past few days . The only thing I can think of is the vaccine as a reason.